

Table SI. Clinical management during pregnancy and postnatally in 3 cases with severe and persistent gestational pemphigoid. In addition to systemic treatment described in the table, all patients received topical glucocorticoids and per oral antihistamine

Case	Gestational age (week)	Time after delivery (month)	Clinical findings	BP180 antibody level (IU/ml) <sup>a</sup>	Prednisolone mg/day (mg/kg/day)	Cyclosporine mg/day (mg/kg/day)	Methotrexate mg/week (mg/kg/week)
1	28+4		Urticarial plaques on trunk, bullous lesions on fingers	89	40 (0.6)		
	32+4		Wide-spread painful lesions, especially on palms and soles	110	40 (0.6)	100 (1.5)	
	34+5		Relieving of symptoms		30 (0.45)	100 (1.5)	
	36+4		Itching, a few new lesions	81	30 (0.45)	Discontinued	
		4.0	Minor pruritic lesions	40	5 (0.7)		
		5.0			Discontinued		
2	31+4		Erythema multiforme-like lesions		20 (0.18)		
	38+4		Bullous lesions on palms and soles	>150	20 (0.18)		
	39+4		Worsening of symptoms		60 (0.55)	300 (2.7)	
		1.5		>150	20 (0.18)	400 (3.6)	
		1.8	Relieving of symptoms		20 (0.18)	300 (2.7)	
		8.0	Provoking symptoms	120	20 (0.18)	300 (2.7)	10 (0.09)
		10.0	No new blisters, mild erythema	70	20 (0.18)	200 (1.8)	15 (0.14)
		12.0	Symptom-free	57	10 (0.09)	Discontinued	15 (0.14)
			Relapse with pruritic papules		20 (0.18)	100 (0.09)	15 (0.14)
		12.5			10 (0.09)	Discontinued	10 (0.09)
	19.0		38	Discontinued		10 (0.09)	
	22.0	Symptom-free	36			Discontinued	
3	27+2		Erythematous, bullous eruption over the body	77	20 (0.33)		
	28+2			110	45 (0.67)		
	29+5		Continuous blistering		45 (0.67)	150 (2.2)	
	34+3		No blistering		35 (0.52)	125 (1.87)	
	35+0		Non-blistering eruption		40 (0.6)	125 (1.87)	
	35+4		Flare-up blistering		40 (0.6)	Discontinued	
	2.0		41	Discontinued			

<sup>a</sup>Bullous pemphigoid antigen 180 (cutoff value 9 IU/ml), Medical & Biological Laboratories, Japan; analysed in HusLab, Helsinki, Finland.